Summaries & Associations of Study Results
TR-406 gamma-Butyrolactone
Target Organs and Levels of Evidence
NTP Technical Report Number 406
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| GAMMA-BUTYROLACTONE 96-48-0 |
07/09/91 | INTERMEDIATE IN THE SYNTHESIS OF POLYVINYLPYRROLIDONE, DL-METHIONINE, PIPERIDINE, PHENYLBUTYRIC ACID, AND THIOBUTYRIC ACIDS. SOLVENT FOR RESINS. CONSTITUENT OF PAINT REMOVERS. TEXTILE AIDS. DRILLING OILS. (TDB) | Gavage MR: 0,112,225, FR: 0,225,450, M: 0,262,525 MG/KG/50 PER GROUP | Southern Research Institute |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: NO EVIDENCE | ||||
| FR: NO EVIDENCE | ||||
| OTHER :CONSIDERATIONS: | MAMMARY GLAND: CYST 42/50 35/50 23/50; FIBROADENOMA 22/50 14/50 6/50 | |||
| PITUITARY GLAND: CYST 25/49 13/37 11/48 | ||||
| MM: EQUIVOCAL EVIDENCE | ADRENAL GLAND MEDULLA: PHEOCHROMOCYTOMA 1/48 5/50 1/50 OR MALIGNANT PHEOCHROMOCYTOMA 1/48 1/50 0/50 COMBINED 2/48 6/50 1/50 | |||
| OTHER :CONSIDERATIONS: | LIVER: ADENOMA 8/50 6/50 1/50 OR CARCINOMA 16/50 2/50 8/50 COMBINED 24/50 8/50 9/50 | |||
| NON-NEOPLASTIC LESIONS: | ADRENAL GLAND: HYPERPLASIA | |||
| FM: NO EVIDENCE | ||||
Web page last updated on February 10, 2006
